Literature DB >> 28408003

Evaluation of Noncompletion Bias and Long-Term Adherence in a 10-Year Patient-Reported Outcome Monitoring Program in Clinical Routine.

Eva Maria Gamper1, Virginie Nerich2, Monika Sztankay3, Caroline Martini3, Johannes M Giesinger3, Lorenza Scarpa4, Sabine Buxbaum4, Martin Jeller4, Bernhard Holzner3, Irene Virgolini4.   

Abstract

BACKGROUND: Currently there is little knowledge on real-life sustainability of routine patient-reported outcome (PRO) measurement and the representativeness of collected data.
OBJECTIVES: The investigation of routine PRO with regard to noncompletion bias and long-term adher- ence, considering the potential impact of mode of assessment (MOA) (paper-pencil vs. electronic PRO [ePRO]) and patient characteristics.
METHODS: At our department, routine PRO measurement in oncological patients is being done since 2005 using different MOA (paper-pencil assessment until 2011 and ePRO assessment from 2011 onward). We analyzed two different patient groups: patients eligible in both periods (both-MOA group) and patients eligible in only one period (one-MOA group). The primary outcome was PRO noncompletion (100% missing questionnaires). The secondary outcome was poor PRO adherence (>20% missing questionnaires). Multivariate logistic regression models were developed, testing the impact of MOA and patient characteristics on the outcomes in the different patient groups.
RESULTS: Data from 1484 eligible patients were included in the analyses. Most of the patients could be included in PRO assessment at least once. PRO noncompletion rates were clearly higher during paper-pencil assessment (odds ratios between 2.72 and 4.31), as were poor PRO adherence rates (odd ratio 2.23). Analyses of potential bias by patient characteristics showed that male patients had a higher risk of poor adherence. Other factors with significant impact were age, country, and cancer diagnosis, but results were indecisive.
CONCLUSIONS: ePRO increased the feasibility of our clinical routine PRO data for retrospective analyses by increasing completion rates. In general, potential completion bias regarding certain patient characteristics requires attention before generalizing results to the respective populations.
Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  clinical routine; evaluation; mode of assessment; patient-reported outcomes

Mesh:

Year:  2017        PMID: 28408003     DOI: 10.1016/j.jval.2017.01.009

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  4 in total

1.  Deep Learning for Cancer Symptoms Monitoring on the Basis of Electronic Health Record Unstructured Clinical Notes.

Authors:  Charlotta Lindvall; Chih-Ying Deng; Nicole D Agaronnik; Anne Kwok; Soujanya Samineni; Renato Umeton; Warren Mackie-Jenkins; Kenneth L Kehl; James A Tulsky; Andrea C Enzinger
Journal:  JCO Clin Cancer Inform       Date:  2022-06

2.  Do reminder emails and past due notifications improve patient completion and institutional data submission for patient-reported outcome measures?

Authors:  Stephanie L Pugh; Joseph P Rodgers; Jennifer Moughan; Roseann Bonanni; Jaskaran Boparai; Ronald C Chen; James J Dignam; Deborah W Bruner
Journal:  Qual Life Res       Date:  2020-09-07       Impact factor: 4.147

3.  Cancer patients' wish for psychological support during outpatient radiation therapy : Findings from a psychooncological monitoring program in clinical routine.

Authors:  D Riedl; R Gastl; E Gamper; C R Arnold; D Dejaco; F Schoellmann; G Rumpold
Journal:  Strahlenther Onkol       Date:  2018-03-12       Impact factor: 3.621

4.  Following patient pathways to psycho-oncological treatment: Identification of treatment needs by clinical staff and electronic screening.

Authors:  Fanny L Loth; Verena Meraner; Bernhard Holzner; Susanne Singer; Irene Virgolini; Eva M Gamper
Journal:  Psychooncology       Date:  2018-03-24       Impact factor: 3.894

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.